Immutep Ltd (PRRUF) Price & Analysis

26 Followers

PRRUF Stock Chart & Stats

$0.04

$0.00(0.00%)

At close: May 26 4:00 PM EDT

$0.04

$0.00(0.00%)

Day’s Range― - ―

52-Week Range$0.02 - $0.33

Previous CloseN/A

Volume11.25K

Average Volume (3M)756.00

Market Cap

$23.83M

Enterprise Value$10.28M

Total Cash (Recent Filing)$68.87M

Total Debt (Recent Filing)$1.05M

Price to Earnings (P/E)―

Beta1.24

Next Earnings

Feb 25, 2027

EPS Estimate

>-0.01

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.05

Shares Outstanding1,474,110,200

10 Day Avg. Volume2,020

30 Day Avg. Volume756

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)1.27

Price to Sales (P/S)5.36

P/FCF Ratio-1.40

Enterprise Value/Market Cap0.43

Enterprise Value/Revenue0.71

Enterprise Value/Gross Profit0.83

Enterprise Value/Ebitda-0.12

Forecast

1Y Price Target

$0.05

Price Target Upside23.01% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)>-0.01

Revenue Forecast (FY)$2.73M

Bulls Say, Bears Say

Bulls Say

Revenue GrowthFY2026 revenue growth of about 144% indicates materially improving commercial traction and a larger potential base for future scale. If this acceleration persists, it can help spread the company’s clinical and operating investment across higher sales, although profitability is not yet established.

Gross Margin ImprovementAn approximately 83% FY2026 gross margin is a substantial improvement versus the negative gross-profit profile in several prior years. This suggests revenue is converting more effectively into gross profit, creating a stronger foundation for eventual operating leverage if expenses become better controlled.

Low LeverageTotal debt of about $1.0M and debt-to-equity near 0.02 keep interest and debt-related balance-sheet pressure limited. Positive equity of roughly $61.5M also provides a capital buffer, giving Immutep more flexibility than a highly leveraged company while it advances its pipeline.

Bears Say

Persistent Net LossesDespite stronger revenue and gross margin, FY2026 net income was a loss of roughly $79.3M, with deeply negative operating and net margins. Persistent losses show that current revenue has not yet covered the company’s operating expense base, leaving profitability dependent on substantial improvement in scale or cost control.

Sustained Cash BurnOperating cash flow was about negative $55.5M and free cash flow about negative $55.6M in FY2026, with free cash flow deteriorating about 11% year over year. This sustained cash consumption means the business remains dependent on external funding until operating scale improves.

Equity ErosionEquity fell from about $143.6M in FY2025 to $61.5M in FY2026, alongside strongly negative return on equity. Continued erosion reduces the balance-sheet buffer available to fund development and increases the risk that future financing could be dilutive if losses persist.

Immutep Ltd News

Immutep presents HRQoL data from EFTISARC-NEO trial

Immutep (IMMP) announced health-related quality of life, or HRQoL, data from the investigator-initiated EFTISARC-NEO Phase II trial. The...

9d ago

IMMP

Immutep, Monash University secure further ARC linkage projects

Immutep (IMMP) announced that the Australian Research Council, or ARC, has awarded Monash University a grant of A$652,248...

18d ago

IMMP

Immutep regains compliance with Nasdaq minimum bid price requirement

Immutep (IMMP) announced that it has received written notification from the Listing Qualifications Department of Nasdaq confirming that...

19d ago

IMMP

Immutep Refocuses Efti Development, Elevates IMP761 as Cash Runway Extends to 2028

Immutep Ltd ( ($AU:IMM) ) has provided an update. Immutep has sharpened its clinical strategy for eftilagimod alfa,...

3d ago

Immutep Sets Date and Agenda for 2026 Annual General Meeting

Immutep Ltd ( ($AU:IMM) ) has issued an announcement. Immutep Limited has called its 2026 Annual General Meeting...

5d ago

Immutep Files Updated Corporate Governance Disclosures for FY2026

An announcement from Immutep Ltd ( ($AU:IMM) ) is now available. Immutep Limited has lodged its Appendix 4G...

5d ago

Immutep Sets Out Governance and Market Footing in 2026 Annual Report

Immutep Ltd ( ($AU:IMM) ) has shared an announcement. Immutep Limited released its Annual Report for the year...

5d ago

Immutep Files 2026 Form 20-F, Confirms Accelerated Filer Status

Immutep Ltd ( ($AU:IMM) ) has shared an announcement. Immutep Limited has filed its annual report on Form...

6d ago

Immutep’s Sarcoma Trial Shows Stable Quality of Life and Post-Surgery Gains

Immutep Ltd ( ($AU:IMM) ) has provided an update. Immutep reported new health-related quality of life data from...

9d ago

Immutep Earns Buy Rating on First-in-Class LAG-3 Agonist IMP761, Strong Phase 1 Data, and Cash Runway Into 2028

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Immutep. The associated price target is...

10d ago

IMMP

Immutep’s First-in-Class LAG-3 Agonist IMP761 Secures Late-Breaking Slot at ACR 2026

The latest announcement is out from Immutep Ltd ( ($AU:IMM) ). Immutep announced that a late-breaking abstract on...

13d ago

Immutep, Monash Win New ARC Grant to Advance LAG-3 Research

Immutep Ltd ( ($AU:IMM) ) has issued an announcement. Immutep Limited has secured further support for its long-running...

18d ago

Immutep Restores Nasdaq Bid Price Compliance with ADS Ratio Change

Immutep Ltd ( ($AU:IMM) ) has issued an update. Immutep Ltd has regained compliance with Nasdaq’s minimum bid...

19d ago

Immutep receives A$856,669 cash rebate from Australia R&D tax incentive program

Immutep (IMMP) announces that it received an A$856,669 cash rebate from the Australian Federal Government’s R&D tax incentive...

1M ago

IMMP

PRRUF FAQ

What was Immutep Ltd’s price range in the past 12 months?

Immutep Ltd lowest stock price was $0.02 and its highest was $0.33 in the past 12 months.

What is Immutep Ltd’s market cap?

Immutep Ltd’s market cap is $23.83M.

When is Immutep Ltd’s upcoming earnings report date?

Immutep Ltd’s upcoming earnings report date is Feb 25, 2027 which is in 116 days.

How were Immutep Ltd’s earnings last quarter?

Immutep Ltd released its earnings results on Sep 02, 2026. The company reported -$0.016 earnings per share for the quarter, missing the consensus estimate of -$0.003 by -$0.013.

Is Immutep Ltd overvalued?

According to Wall Street analysts Immutep Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immutep Ltd pay dividends?

Immutep Ltd does not currently pay dividends.

What is Immutep Ltd’s EPS estimate?

Immutep Ltd’s EPS estimate is >-0.01.

How many shares outstanding does Immutep Ltd have?

Immutep Ltd has 1,474,110,200 shares outstanding.

What happened to Immutep Ltd’s price movement after its last earnings report?

Immutep Ltd reported an EPS of -$0.016 in its last earnings report, missing expectations of -$0.003. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Immutep Ltd?

Currently, no hedge funds are holding shares in PRRUF

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Immutep Ltd Stock Smart Score

Neutral

Fundamentals

Return on Equity

-98.86%

Trailing 12-Months

Asset Growth

-43.93%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Immutep Ltd

Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company’s product pipeline also includes TACTI-004, which is in phase III clinical trial for the treatment of first line non-small cell lung cancer (1L NSCLC); TACTI-003, which is in phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (HNSCC); INSIGHT-005 which is in phase I for metastatic urothelial carcinoma; TACTI-002, which in phase II trial for the treatment NSCLC and HNSCC; AIPAC-003, which is in phase II/III clinical trial to treat metatastic breast cancer; and EFTISARC-NEO, which is in phase II clinical trial for the treatment of soft tissue sarcoma. It also develops INSIGHT-003, which is in phase I trial 1L non squamous NSCL; INSIGHT-005 that is in phase I to treat metastatic urothelial cancer; IMP761, which is in phase I Trial to treat autoimmune disease; IMP731 for oncology and autoimmune diseases; and LAG525. Immutep has collaboration with Merck & Co., Inc., EOC Pharma, Novartis, and Laboratory Corporation of America Holdings. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. The company was incorporated in 1987 and is based in Sydney, Australia.

Immutep Ltd (PRRUF) Earnings & Revenues

Historic Earnings Reports

PRRUF Stock 12 Month Forecast

Average Price Target

$0.05

▲(23.01% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","1":"$1","-1":"-$1","-0.5":"-$0.5","0.5":"$0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.056232,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$0.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.049203,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$0.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.042174,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$0.04</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.03,0.032017846153846154,0.03403569230769231,0.03605353846153846,0.03807138461538462,0.040089230769230766,0.04210707692307692,0.044124923076923075,0.04614276923076923,0.048160615384615385,0.05017846153846154,0.052196307692307695,0.05421415384615384,{"y":0.056232,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.03,0.03147715384615384,0.03295430769230769,0.034431461538461536,0.035908615384615386,0.03738576923076923,0.03886292307692307,0.04034007692307692,0.041817230769230766,0.04329438461538461,0.04477153846153846,0.0462486923076923,0.047725846153846146,{"y":0.049203,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.03,0.030936461538461538,0.031872923076923076,0.032809384615384615,0.033745846153846154,0.03468230769230769,0.03561876923076923,0.03655523076923077,0.03749169230769231,0.03842815384615385,0.03936461538461539,0.040301076923076926,0.041237538461538464,{"y":0.042174,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.194,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.201,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.18,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.321,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.253,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.253,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.04,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.05,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.05,"date":1780272000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.05,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.05,"date":1785542400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.037,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.03,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >